17th Winter Conference
on Medicinal & Bioorganic Chemistry

Chemical Tailoring at C—H Bonds

Synthesis Innovation in Drug Discovery

Inserting, Deleting, and Replacing Atoms

Recent Advances in DNA-Encoded Technology at GSK

Living in Uncertainty: Application of Active Learning in Drug Discovery

Redefining Druggability with Induced Proximity Modalities

Hold and Kill: RIPTAC™ Therapeutics Present a Novel Induced-Proximity Mechanism to Conquer Cancer

Discovery of Orally Bioavailable SMARCA2-Selective Monovalent Degraders

The Hunt for Ligands for Tissue-Restricted Ligases

Cereblon Mediated Ligand Directed Degradation at Bristol Myers Squibb

Discovery of C-terminal and N-terminal binding STING agonists

Switching the Immune System Off and On Through Computationally Enabled Drug Discovery: The Discovery of TYK2 Inhibitor TAK-279 for Immune Disorders and HPK1 Inhibitor NDI-101150 for Cancer

Development of Non-alkynyl NIK Inhibitors

Discovery and Optimization of a Series of MALT1 Inhibitors Using Structure-Based Drug Design and Parallel Medicinal Chemistry

Redefining Selectivity in JAK1 Inhibition: The Case for Allosteric Modulators

Discovery of a Non-Covalent Inhibitor of the Coronavirus Main Protease

Catalyzing Molecular Invention Leveraging Industry-Academia Collaborations

Covalent Modulators of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ): Towards A New Targeted Cancer Therapy

Discovery of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK-Inhibitor for the Treatment of MS

Discovery of Potent and Selective CDK2 Inhibitors Utilizing a Novel Molecular Dynamics Based Approach

Bioconjugation Tools for Protein Modifications

Advances in chemical and enzymatic bioconjugation to enable antibody conjugate drugs

The Magic of Legumain Cleavable Peptides: New ADC Linker Designs for Diverse Applications

Technology and Platform Development for ADC Conjugations

Targeted Delivery of BCL-X_L Selective Inhibitors Alleviates On-Target Toxicity of Systemically Dosed Inhibitors in Preclinical Models

Covalent Protein Degraders Targeting the Cereblon Sensor Loop Histidine

Approaches to Targeting RNA with Small Molecules

Large-Scale Chemoproteomics Expedites Drug Discovery and Predicts Ligand Behavior in Cells

KEYNOTE:  Overcoming the Undruggable Nature of the Most Common Human Oncogene K-Ras

Neutral Transthyretin (TTR) Stabilizers for the Treatment of Amyloidogenic Diseases

Impacting Protein Homeostasis Through Covalent Modification: Discovery of a Small Molecule Degrader for the Treatment of MAFLD

Discovery of ABBV-992:  A Covalent BTK Inhibitor for the Treatment of B-cell Lymphoma

Discovery of MK-8527: A Novel Nucleoside Reverse Transcriptase Translocation Inhibitor for Long-acting HIV Pre-exposure Prophylaxis

Discovery of inhaled sGC Activator Mosliciguat for the Treatment of Pulmonary Hypertension